Published date: 20 October 2021
Awarded contract - This means that the contract has been awarded to a supplier.
Contract summary
Industry
Vaccines - 33651600
Location of contract
United Kingdom
Value of contract
£1
Procurement reference
2611/09/2020
Published date
20 October 2021
Closing date
19 September 2021
Closing time
11:59pm
Contract start date
20 September 2021
Contract end date
31 December 2022
Contract type
Supply contract
Procedure type
Single tender action (below threshold)
A direct contract with a single supplier, without competition.
This procedure can be used for procurements below the relevant contract value threshold.
Contract is suitable for SMEs?
No
Contract is suitable for VCSEs?
No
Description
Procurement of the Covid-19 Adjuvanted Pandemic Vaccine.
More information
Previous notice about this procurement
Capacity Reservation Agreement
- Awarded contract
- Published 18 May 2021
Attachments
-
- Advance Purchase Agreement - [REDACTED].pdf
- Signed contract
Additional text
-
Contract end date is being withheld on grounds that release would be contrary to public interest (Reg 50(6)(a)) and commercial sensitivity (Reg 50(6)(b) and (c)). The date is variable based on production and delivery. Given significant challenges to overcome, the end date may set unrealistic expectation for the public/market.
Award information
Awarded date
20 September 2021
Contract start date
20 September 2021
Contract end date
31 December 2022
Total value of contract
£1
This contract was awarded to 2 suppliers.
Aventis Pharma Ltd
Address
Thames Valley Park Drive
Reading
Berkshire
RG6 1PTReference
Companies House number: 01535640
Supplier is SME?
No
Supplier is VCSE?
No
GlaxoSmithKline Biologicals S.A
Address
Rue de l'Institut 89
Rixensart
B-1330Reference
No reference - other
Supplier is SME?
No
Supplier is VCSE?
No
Additional details
-
National registration number: BE 0440.872.918
Share this notice
Closing: 19 September 2021, 11:59pm
All content is available under the
